Phoenix, AZNCT07764978Now EnrollingIRB Ready

Newly Diagnosed Multiple Myeloma Clinical Trial in Phoenix, AZ

Access cutting-edge newly diagnosed multiple myeloma treatment through this phase 3 clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access newly diagnosed multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related newly diagnosed multiple myeloma treatment provided free

Apply for This Phoenix Location

Check if you qualify for this newly diagnosed multiple myeloma clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Newly Diagnosed Multiple Myeloma Study in Phoenix

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participants must be 18 years or older, at the time of signing the ICF.
Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria.
Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio.
Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.
Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator.
ECOG performance status Grade of 0 to 2.
Participant must have adequate organ and bone marrow function.

Exclusion Criteria

Participant has active or prior CNS or meningeal involvement of MM.
Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome.
Participant has significant neurological or psychiatric condition posing risk or impairing evaluation.
Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation.
Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
Participant is positive for any of the following:
HIV: Known to be seropositive for HIV (including any history of HIV).
Chronic or active hepatitis B.
Active hepatitis C: Hepatitis C infection.
Additional local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations.
Participant has clinically significant cardiovascular disease.
Participant has COPD with an FEV1 \< 50% of predicted normal.
Additional exclusion for participants who are planned to receive IsaVRd as induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade 1 with pain.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT07764978) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Newly Diagnosed Multiple Myeloma Treatment Options in Phoenix, AZ

If you're searching for newly diagnosed multiple myeloma treatment options in Phoenix, AZ, this clinical trial (NCT07764978) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced newly diagnosed multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all newly diagnosed multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Phoenix, AZ

See all multiple myeloma clinical trials recruiting in Phoenix — not just this study.

Browse Multiple Myeloma Trials in Phoenix →

Browse More Trials by Condition

Multiple Myeloma TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ